Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...308309310311312313314315316317318...10671068»
  • ||||||||||  Xpovio (selinexor) / Karyopharm, Menarini
    Review, Journal, IO biomarker:  The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma. (Pubmed Central) -  Jun 8, 2022   
    Clinical studies have demonstrated that the XPO1 inhibitor selinexor can restore sensitivity of RR-MM to PIs and dexamethasone. We will elaborate on the problems of MM treatment strategies and discuss the mechanism and challenges of using XPO1 inhibitors in RR-MM therapies while deliberating potential solutions.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Trial completion, Enrollment change, Trial completion date:  TOCIDEX: Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19 (clinicaltrials.gov) -  Jun 8, 2022   
    P2,  N=453, Completed, 
    We will elaborate on the problems of MM treatment strategies and discuss the mechanism and challenges of using XPO1 inhibitors in RR-MM therapies while deliberating potential solutions. Recruiting --> Completed | N=660 --> 453 | Trial completion date: Dec 2021 --> Aug 2021
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Sexual Dimorphism of Dexamethasone as a Prophylactic Treatment in Pathologies Associated With Acute Hypobaric Hypoxia Exposure. (Pubmed Central) -  Jun 8, 2022   
    Thus, for the first time, this study shows a sex-biased regulation by dexamethasone of physiologic parameters resulting from the hypoxic environment of high-altitude, which impacts the development of high-altitude pulmonary hypertension and acute mountain sickness. Future studies of cellular contributions toward sex-specific regulation may provide further insights and preventive measures in managing sex-specific, high-altitude-related disorders.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Late night salivary cortisol and cortisone should be the initial screening test for Cushing's syndrome. (Pubmed Central) -  Jun 8, 2022   
    We present a retrospective study in a tertiary referral centre comparing LNSC, LNS cortisone, overnight dexamethasone suppression test, low dose dexamethasone suppression test and 24-hour urinary free cortisol results of patients investigated for CS...Saliva collection is non-invasive and can be carried out at home. We therefore advocate simultaneous measurement of LNSC and LNS cortisone as the first-line screening test to evaluate patients with suspected CS.
  • ||||||||||  Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrronium) / AstraZeneca
    Trial completion date, Trial primary completion date, Real-world evidence, Patient reported outcomes, Real-world:  RECORD: REported Outcomes in COPD With Trixeo in Real worlD (clinicaltrials.gov) -  Jun 8, 2022   
    P=N/A,  N=500, Not yet recruiting, 
    We therefore advocate simultaneous measurement of LNSC and LNS cortisone as the first-line screening test to evaluate patients with suspected CS. Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2023 --> Mar 2024
  • ||||||||||  Xpovio (selinexor) / Karyopharm
    Trial completion date, Trial primary completion date, Combination therapy:  STOMP: Selinexor and Backbone Treatments of Multiple Myeloma Patients (clinicaltrials.gov) -  Jun 6, 2022   
    P1b/2,  N=518, Recruiting, 
    Active, not recruiting --> Completed Trial completion date: May 2022 --> Jan 2025 | Trial primary completion date: May 2022 --> Jan 2025
  • ||||||||||  hydrocortisone / Generic mfg.
    Trial completion date, Trial primary completion date:  MsSCORE: Effects of Glucocorticoids on Cognition in HIV-infected Women (clinicaltrials.gov) -  Jun 6, 2022   
    P1,  N=148, Recruiting, 
    Trial completion date: May 2022 --> Jan 2025 | Trial primary completion date: May 2022 --> Jan 2025 Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: May 2022 --> May 2023
  • ||||||||||  Darzalex (daratumumab) / J&J
    Trial completion date, Trial primary completion date, Combination therapy:  CARO: Non-interventional Study of Kyprolis (clinicaltrials.gov) -  Jun 6, 2022   
    P=N/A,  N=409, Recruiting, 
    Trial completion date: May 2022 --> May 2023 | Trial primary completion date: May 2022 --> May 2023 Trial completion date: Sep 2024 --> Jun 2025 | Trial primary completion date: Sep 2024 --> Jun 2025
  • ||||||||||  Trial initiation date:  Effect of Corticosteroid Injections on Blood Glucose (clinicaltrials.gov) -  Jun 5, 2022   
    P2,  N=124, Not yet recruiting, 
    Trial completion date: Sep 2024 --> Jun 2025 | Trial primary completion date: Sep 2024 --> Jun 2025 Initiation date: Apr 2022 --> Oct 2022
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Th17-Dependent Nasal Hyperresponsiveness Is Mitigated by Steroid Treatment. (Pubmed Central) -  Jun 5, 2022   
    We challenged the transferred mice by intranasal injection of OVA and to some of them, administered dexamethasone (Dex) subcutaneously in advance...Allergen-induced INR and NHR were significantly suppressed by Dex treatment. This study suggested the effectiveness of steroids on Th17 cell-mediated nasal responses in AR.
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal:  Effect of Prenatal Glucocorticoid Exposure on Circadian Rhythm Gene Expression in the Brains of Adult Rat Offspring. (Pubmed Central) -  Jun 5, 2022   
    Results from the current study show that prenatal exposure to Dex affects circadian rhythm gene expression in a brain region-specific and a sex-specific manner within molecular oscillators of the amygdala, hippocampus, paraventricular nucleus, and prefrontal cortex, as well as the main oscillator in the SCN. Results also show that spontaneously hypertensive rats (SHR) exhibited dysregulated circadian rhythm gene expression in these same brain regions compared with normotensive Wistar-Kyoto rats (WKY), although the pattern of dysregulation was markedly different from that seen in adult offspring prenatally exposed to GCs.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Iminosugar Amino Acid idoBR1 Reduces Inflammatory Responses in Microglia. (Pubmed Central) -  Jun 5, 2022   
    A mouse BV-2 microglia cell line was activated using LPS and the anti-inflammatory cucumber-derived iminosugar amino acid idoBR1, (2R,3R,4R,5S)-3,4,5-trihydroxypiperidine-2-carboxylic acid, was used alongside dexamethasone as the control to determine whether it could reduce the inflammatory responses...(4) Conclusions. Further investigations of the anti-inflammatory effects of idoBR1 in other models of neurodegenerative diseases are warranted.